About The Study: The findings of this study suggest a narrowing of racial and ethnic disparities in receipt of ERBB2 (formerly HER2 or HER2/neu)-targeted therapies over time among older Medicare ...

Racial and ethnic disparities in the use of targeted therapy among patients with ERBB2-positive breast cancer decreased among older Medicare beneficiaries between 2010 and 2019. Black and Hispanic ...

Interestingly, when ErbB2 is overexpressed, heterodimers form preferentially. Unlike homodimers, which are either inactive (ErbB3 homodimers) or signal only weakly, ErbB2-containing heterodimers ...

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...

Additionally, they unveiled a brain-penetrant ErbB2 inhibitor with potential best-in-class properties. The company also appointed Ray Frost as Senior Vice President, Market Access, and Adam Boyd ...

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...

Data presented included an objective response rate (ORR) of 71%, with 7% of patients achieving complete responses (CR), and a 96% disease control rate (DCR) Previously unreported results ...

New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of Medicine Data presented included an objective response rate (ORR ...

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...